IN2012DN03187A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03187A
Authority: IN; India
Prior art keywords: present; glp; treat; muscle atrophy; prevent muscle
Prior art date: 2009-10-07

Application number

Other languages

English (en)

Inventor

Didier Attaix

Audrey Codran-Raison

Irene Corthesy-Theulaz

Denis Breuille

Lydie Combaret

Original Assignee

Nestec Sa

I N R A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-07

Filing date

2010-10-07

Publication date

2015-09-25

2010-10-07 Application filed by Nestec Sa, I N R A filed Critical Nestec Sa

2015-09-25 Publication of IN2012DN03187A publication Critical patent/IN2012DN03187A/en

Links

239000000203 mixture Substances 0.000 abstract 3
102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 2
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 2
206010028289 Muscle atrophy Diseases 0.000 abstract 2
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 2
230000020763 muscle atrophy Effects 0.000 abstract 2
201000000585 muscular atrophy Diseases 0.000 abstract 2
230000035764 nutrition Effects 0.000 abstract 1
235000016709 nutrition Nutrition 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Polymers & Plastics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Food Science & Technology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN3187DEN2012 2009-10-07 2010-10-07 IN2012DN03187A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09172398A EP2311486A1 (en)	2009-10-07	2009-10-07	GLP-2 for use in intestine and muscle recovery
PCT/EP2010/065021 WO2011042501A2 (en)	2009-10-07	2010-10-07	The intestine and muscle recovery

Publications (1)

Publication Number	Publication Date
IN2012DN03187A true IN2012DN03187A (pt)	2015-09-25

Family

ID=41611235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3187DEN2012 IN2012DN03187A (pt)	2009-10-07	2010-10-07

Country Status (11)

Country	Link
US (1)	US20120270786A1 (pt)
EP (2)	EP2311486A1 (pt)
JP (1)	JP5801814B2 (pt)
CN (1)	CN102711803B (pt)
AU (1)	AU2010305420B2 (pt)
BR (1)	BR112012009380A2 (pt)
CA (1)	CA2776964C (pt)
DK (1)	DK2485756T3 (pt)
ES (1)	ES2539917T3 (pt)
IN (1)	IN2012DN03187A (pt)
WO (1)	WO2011042501A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2986156B2 (en) *	2013-04-15	2020-06-03	Société des Produits Nestlé S.A.	Use of whey protein in combination with electrical muscle stimulation
JP6325215B2 (ja) *	2013-08-29	2018-05-16	テルモ株式会社	栄養補給用冷菓
BR112017005762B1 (pt) *	2014-10-14	2021-10-05	Société des Produits Nestlé S.A.	Composição compreendendo uma fonte de proteína, e um antioxidante e seu uso
KR101661332B1 (ko) *	2015-05-28	2016-09-29	(의료)길의료재단	글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
US10993993B2 (en)	2015-05-28	2021-05-04	Immunoforge Co., Ltd.	Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
KR102119188B1 (ko) *	2018-11-13	2020-06-08	이뮤노포지 주식회사	글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5661123A (en) *	1995-01-17	1997-08-26	Nestec, Ltd.	Enteral composition for malabsorbing patients
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) *	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
EP2275438A1 (en) *	1996-04-12	2011-01-19	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
CA2223198A1 (en) *	1997-01-14	1998-07-14	Societe Des Produits Nestle S.A.	Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
CA2236519C (en) *	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
EP1090636A1 (en) *	1999-09-13	2001-04-11	Société des Produits Nestlé S.A.	High lipid diet
PT1326630E (pt) *	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
US7186683B2 (en) *	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
DK1360202T3 (da) *	2001-02-16	2008-09-22	Conjuchem Biotechnologies Inc	Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
KR20050059258A (ko) *	2002-10-14	2005-06-17	노보 노르디스크 에이/에스	Ｇｌｐ-2 화합물, 제제, 및 그것의 사용
US20040115708A1 (en) *	2002-10-28	2004-06-17	Ardies C. Murray	Method of screening agents for the treatment and prevention of cancer and cachexia and the new use of specific agents for the treatment and prevention of cancer and cachexia
EP1633384B1 (en) *	2003-05-15	2012-03-14	Trustees Of Tufts College	Stable analogs of glp-1
CN101175416A (zh) *	2005-04-06	2008-05-07	诺瓦提斯公司	从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物
EP1971230A2 (en) *	2006-01-09	2008-09-24	Nestec S.A.	Treatment of stressed patients
AU2007319066B2 (en) *	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues

2009
- 2009-10-07 EP EP09172398A patent/EP2311486A1/en not_active Withdrawn
2010
- 2010-10-07 DK DK10762684.8T patent/DK2485756T3/en active
- 2010-10-07 CA CA2776964A patent/CA2776964C/en active Active
- 2010-10-07 AU AU2010305420A patent/AU2010305420B2/en active Active
- 2010-10-07 JP JP2012532595A patent/JP5801814B2/ja active Active
- 2010-10-07 ES ES10762684.8T patent/ES2539917T3/es active Active
- 2010-10-07 WO PCT/EP2010/065021 patent/WO2011042501A2/en not_active Ceased
- 2010-10-07 US US13/500,784 patent/US20120270786A1/en not_active Abandoned
- 2010-10-07 BR BR112012009380-0A patent/BR112012009380A2/pt not_active Application Discontinuation
- 2010-10-07 IN IN3187DEN2012 patent/IN2012DN03187A/en unknown
- 2010-10-07 EP EP10762684.8A patent/EP2485756B1/en active Active
- 2010-10-07 CN CN201080055259.6A patent/CN102711803B/zh active Active

Also Published As

Publication number	Publication date
AU2010305420B2 (en)	2015-03-19
DK2485756T3 (en)	2015-06-08
EP2311486A1 (en)	2011-04-20
BR112012009380A2 (pt)	2021-06-22
EP2485756B1 (en)	2015-05-20
WO2011042501A3 (en)	2011-06-03
CA2776964C (en)	2019-03-05
HK1173949A1 (en)	2013-05-31
WO2011042501A2 (en)	2011-04-14
CN102711803A (zh)	2012-10-03
EP2485756A2 (en)	2012-08-15
JP5801814B2 (ja)	2015-10-28
US20120270786A1 (en)	2012-10-25
CA2776964A1 (en)	2011-04-14
AU2010305420A1 (en)	2012-05-10
ES2539917T3 (es)	2015-07-07
JP2013507341A (ja)	2013-03-04
CN102711803B (zh)	2017-02-22

Publication	Publication Date	Title
IL268519A (en)	2019-09-26	Useful preparations in the treatment of spinal muscular atrophy
IN2012DN02624A (pt)	2015-05-22
IN2012DN01638A (pt)	2015-06-05
MX343135B (es)	2016-10-25	Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
IL210810A0 (en)	2011-04-28	Compositions for the treatment of pain and/or inflamtion
MY198422A (en)	2023-08-29	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY153948A (en)	2015-04-15	Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX2011007930A (es)	2011-09-06	Conjugados de insulina cristalina.
EP2384198A4 (en)	2012-08-08	PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES
IN2012DN00624A (pt)	2015-06-12
IL184312A0 (en)	2008-01-20	Herbal compositions for the treatment of diabetes and/or conditions associated therewith
MX364173B (es)	2019-04-15	Compuestos, composiciones y metodos para proteger la salud cerebral en trastornos neurodegenerativos.
GB2480042A (en)	2011-11-02	Prebiotic formulations and methods of use
SG10201408158SA (en)	2015-03-30	Composition and methods used during anti-hiv treatment
MX2011009539A (es)	2012-02-21	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
PH12013502261A1 (en)	2022-10-26	Partially saturated tricyclic compounds and methods of making and using same
MY150602A (en)	2014-01-30	Subtituted-quinoxaline-type piperidine compounds and the uses thereof
HK1221171A1 (zh)	2017-05-26	用於刺激骨生长的组合物
TN2012000059A1 (en)	2013-09-19	Compositions comprising tramadol and celecoxib in the treatment of pain
MX2016008226A (es)	2017-02-28	Metodos para el cuidado oral prebiotico usando un sacarido.
WO2011042501A3 (en)	2011-06-03	Glp-2 for use in intestine and muscle recovery
WO2011044523A3 (en)	2014-03-27	Compositions and methods for treating obesity
ZA201109086B (en)	2013-05-29	Prevention and treatment of allergic diarrhoea
MX2011011860A (es)	2011-12-08	Composicion estimulante inmune que comprende un extracto de aronia sp. en combinacion con selenio y/o zinc.
MX2016005092A (es)	2016-08-17	Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos.